

## Randomisation

## Randomisation: Blinded

- The SOPHIST trial is double blinded; all participants and trial staff are blinded to allocation.
- Unblinding will only occur in an emergency, for reporting of SUSARs and at the end of the trial after data lock has occurred.
- Participants will not be able to request to be unblinded.
- Participants will be informed of the results of the trial and their treatment allocation once the trial results have been published.

## TRuST – Tayside Randomisation System

- Web-based randomisation system used by Research Nurses.
- Trial Manager and trial monitors have access to TRuST to enable them to check blinded randomisation and drug accountability details remotely.
- Research Nurses will use TRuST for the following:
  - Randomisation of participants.
  - Overview of randomisation details.
  - Overview of pack allocation for site and/or participant.

## Randomisation: Requirement

- Delegated to randomise on Delegation Log.
- Randomisation training completed – this presentation and read the TRuST User Guide.
- Medical Record signed by PI/delegate confirming eligibility.
- Internet access/TRuST log-in.
- Participant ID, gender, initials (i.e. for first and last name), date of birth and eligibility.
- Printer.

## Randomisation: TRuST System


- TRuST can be accessed directly <https://trust.hicservices.dundee.ac.uk> or from the SOPHIST trial website resources page <https://sites.dundee.ac.uk/sophist-trial/sophist-trial-resources/>
- Login details will be sent out after training has taken place. If not received, click on “Forgotten Password” and enter your email as your username.

- Login with your details; on first login you will be asked to change your password.




If you forget your password, click the forgotten password link and your new password will be emailed to you.

For staff with multiple projects on TRuST select the SOPHIST trial from the dropdown menu.




# Randomising a participant



The screenshot shows the Trust Tayside Randomisation System interface. At the top, the 'trust' logo is displayed with the text 'Tayside Randomisation SysTem' below it. The main content area is titled 'Project: SOPHIST Test' and 'TEST SITE'. Below this, the 'Site: Site 2' is indicated. Under the 'RANDOMISATION' section, three buttons are visible: 'Randomise Participant' (highlighted with a red border), 'Randomisation Details', and 'Drug Accountability'.

- Main menu.
- Click randomise participant.

# Randomising a participant



**RANDOMISE PARTICIPANT**

Participant Identifiers

Initials:    
*First and last initial should be entered*

Date of Birth (DD/MM/YYYY):

Gender:  Male  Female

Eligibility Criteria

Does participant take insulin dose  $\geq 0.5$  units/kg body weight at screening OR has a BMI  $\geq 25$ kg/m<sup>2</sup> at screening?  Yes  No

Does participant have elevated N-terminal pro-B-type natriuretic peptide ( $\geq 400$  ng/L for those in atrial fibrillation/flutter,  $\geq 250$  ng/L for those in all other rhythms) or B-type natriuretic peptide ( $\geq 100$  ng/L for those in atrial fibrillation/flutter,  $\geq 75$  ng/L for those in all other rhythms) within 12 months of screening?  Yes  No

Did participant have one episode of diabetic ketoacidosis or nonketotic hyperosmolar state within 1 month of screening **OR** between screening and randomisation, or  $\geq 2$  diabetic ketoacidosis or nonketotic hyperosmolar state events within 6 months of screening?  Yes  No

[Return to Main Menu](#) [Next](#)

- Enter participant identifiers.
- Complete eligibility criteria questions.
- Click “Next”.



# Randomising a participant



## RANDOMISE PARTICIPANT

Site: Site 2

Participant ID: 02

Does the participant have atrial fibrillation?:  Yes

No

Estimated Glomerular Filtration Rate (eGFR) at screening (ml/min/1.73m2):  25-59

equal to or more than 60

Haemoglobin A1c (HbA1c) at screening (mmol/mol):  less than or equal to 69

more than 69

Most recent Left Ventricular Ejection Fraction (LVEF) (%):  less than or equal to 40

more than 40

Has the CI/PI signed medical records to confirm eligibility of participant  Yes  No

Does the participant meet eligibility criteria?  Yes  No

- Enter participant ID. The first number is provided and is the site number. Enter the 3 further digits. E.g. for the first patient consented enter “001”.
- If unsure about Participant ID consult site enrolment and randomisation log.
- Complete randomisation questions
- **It is an MHRA and GCP requirement that a medical doctor confirms eligibility prior to randomisation.**
- Click “Randomise” button

## Randomising a participant



RANDOMISE PARTICIPANT

Site: Site 2

Subject Identifier: 02005

Randomisation Allocation: Participant Successfully Randomised

Pack ID: 1017  
2017

[Return to Main Menu](#)

- Randomisation notification will be displayed.
- You will receive an email confirming this allocation.
- Pack IDs are generated.



University  
of Dundee



## Insufficient IMP stock

- If the Pack Allocation does not display any pack IDs, this indicates that your site has no remaining stock for that treatment allocation.
- If the number of pack IDs listed under Pack Allocation is less than the correct amount for the treatment, this indicates that your site has insufficient stock of the randomised treatment.
- **Do not proceed with the randomisation and contact the trial manager immediately.**

# Clinical Trial Request/Release Form – (Visit 3)

- This form is not generated by TRuST.
- Research nurse should complete the participant details & fill out the Pack IDs.
- The SOPHIST Clinical Trial Request/Release form must be signed by the PI or their delegate named on the Delegation Log.
- Take the completed SOPHIST Clinical Trial Request/Release form to the Clinical Trials Pharmacy along with a printed copy of the randomisation email generated by TRuST.
- The clinical trial request form should be filed in the PSF.



SOPHIST (Sotagliflozin in Patients with Heart failure Symptoms and Type 1 Diabetes)

## CLINICAL TRIAL REQUEST/RELEASE FORM FOR PHARMACY

IRAS	1007807	Sponsor	University of Dundee and NHS Tayside
Protocol No.		Local CTP ID	

Chief Investigator	Dr Ify Mordi	Tel No	01382385591
Principal Investigator		Tel No	

Participant trial ID:			
Participant Name:			
Date of Birth:		CHI/hospital number:	
Visit Number:		Visit Date:	

<b>Sotagliflozin 200mg or Placebo 200mg</b>	
Total number of tablets:	120 (one bottle of 90 tablets and one bottle of 30 tablets)
Pack ID:	
Pack ID:	
Dosage schedule:	1 tablet per day for a total of 16 weeks

PI or delegate doctor's signature:	Date:
Print name:	

Released By:	Date:
Checked By:	Date:
Collected By:	Date:

SOPHIST IMP Request-Release Form V1 22-02-2024.docx



# Site Randomisation Details

- To check the randomisation details go back to main menu and click the “Randomisation Details” button.



Project: SOPHIST Test

**TEST SITE**

Site: Site 2

RANDOMISATION

Randomise Participant **Randomisation Details** Drug Accountability

- Details of all participants randomised at site will be shown.

# Drug Accountability



- To check Drug Accountability for participants at site (i.e. display participant ID and pack IDs without treatment allocation) go back to main menu and click the Drug Accountability button.



- Drug accountability can be checked for “site” or individual “participant” from a dropdown menu.

- To check drug accountability for an individual participant select “Participant” from the dropdown menu.
- Select participant ID.
- Click “Confirm Participant ID”.



### DRUG ACCOUNTABILITY

Select Accountability by:

Select Participant:

Confirm Participant ID

Confirm Participant ID: 02005

[Return to Main Menu](#)



### DRUG ACCOUNTABILITY

Select Accountability by:

Participant ID: 02005

Participant ID	Pack ID	Date Allocated	By
02005	1017	02/07/2024	sophistRandomise02
02005	2017	02/07/2024	sophistRandomise02

[Return to Main Menu](#)

Please contact the trial management team if you have any questions or issues:

[SOPHIST-trial@dundee.ac.uk](mailto:SOPHIST-trial@dundee.ac.uk)